PDB18 ECONOMIC EVALUATION OF DRUG THERAPY AMONG DIABETES MILLITUS PATIENTS IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL, SAGAMU, OGUN  by Suleiman, IA & Oloyede, FF
357Abstracts
ences in costs between HbA1c groups were analyzed using a gen-
eralized linear model (GLM), controlling for demographics,
patient severity, as well as comorbidities and complications.
RESULTS: In total, 79% of individuals in the analysis obtained
good HbA1c (HbA1c of less than or equal to seven) control at
some time during the post-period although only 59% of these
individuals maintained this level of glycemic control for the dura-
tion of follow-up. Individuals in the fair (HbA1c greater than
seven to less than or equal to nine) or poor (HbA1c greater 
than nine) groups had signiﬁcantly higher diabetes related 
total medical costs compared to individuals with good glycemic
control ($1641 v. $1372 per member per year [PMPY]; p < 0.05;
$1705 v. $1372 PMPY; p < 0.05, respectively). CONCLU-
SIONS: Although initially successful at obtaining good glycemic
control, a large percentage of individuals were unable to main-
tain such control. This is coupled with a ﬁnding of higher dia-
betes-related medical costs for individuals at sub-optimal levels
of control. These results suggest that novel therapies which
improve the capability of individuals to achieve and maintain
glycemic control may have positive ﬁnancial as well as health
implications.
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OBJECTIVES: To evaluate the effect of symptoms of diabetic
peripheral neuropathy (SDPN), diabetic retinopathy (DR) and
co-morbid SDPN & DR (COMORB) among US adults ≥40 years
old with diagnosed diabetes on several burden of illness (BOI)
measures, including indirect costs and health care utilization,
using the combined 1999–2000 and 2001–2002 National Health
and Nutrition Examination Surveys (NHANES). METHODS:
Included in the analysis were 850 NHANES respondents ≥40
years old classiﬁed as having diagnosed diabetes. Logistic 
regression models were used to assess the effect of SDPN, DR
and COMORB on BOI. Model covariates included age, gender,
race, education, insurance status, current smoking status, cur-
rently asthmatic, and history of cardiovascular disease, cancer,
arthritis, COPD, hypertension and stroke. The conditions of
interest were assessed based upon respondent self-report.
RESULTS: Using the combined 1999–2000 and 2001–2002
NHANES, it was estimated that, among US adults ≥40 years old
with diagnosed diabetes, those with SDPN (OR = 2.27; 95% CI
= 1.34, 3.85), DR (1.67; 1.08, 2.59) and COMORB (2.88; 1.28,
6.48) were each more likely to have four or more health care
visits in the past year than those without the corresponding 
condition. Those with DR (1.81; 1.31, 2.50) and COMORB
(2.07; 1.13, 3.77) were both more likely to have had at least 
one overnight hospital stay in the past year. Finally, those of
working age (40–65) with SDPN (3.39; 1.66, 6.89), DR (3.08;
1.55, 6.11) and COMORB (4.51; 2.27, 8.96) were each more
likely to be unable to work due to physical limitations. CON-
CLUSION: Among US adults ≥40 years old with diagnosed dia-
betes, SDPN, DR, and COMORB all appear to signiﬁcantly
increased BOI. Future therapies that offer relief of both of these
conditions may have signiﬁcant beneﬁts on indirect costs (such
as lost work time) and direct measures of health care resource
utilization.
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OBJECTIVE: To carry out economic evaluation of drug therapy
among diabetic patients. METHODS: The methodology was
Cost of Illness Analysis. Out–Patients were considered. Drug
review was carried out retrospectively for randomly sampled 37
case notes over one-year period. Demographic data were col-
lected and number of hospital visits, fasting blood sugar and
blood pressure at each visit, drugs prescribed at each visit. Cost
components were the direct costs. These include the total cost of
drugs over one-year period, personnel cost, diagnostic costs, and
transport cost. Hospital cost of the drugs were used, cost per
deﬁned daily dose of each drugs were calculated as well as the
total drug cost, taken the duration of therapy into consideration.
Stop-watch-time studies and monthly earnings were used in the
calculation of personnel cost. Since the study covers one year
period (July, 2003–August, 2004) neither discounting nor inﬂa-
tion were considered in the analysis. RESULTS: Most of the
patients were Type-II Diabetes Mellitus (n = 33; 89.2%) while
Type-I (insulin required) were four (10.8%). In total, 83.8%
were hypertensive. Total costs of drugs = N1,219,932.70 (US
$8,713.81), Anti-diabetic drugs = N689,231.50 (US $4,923.82)
(56.5%), Anti-hypertensive drugs = N530,701.20 (US $3,790)
(44.5%), Transport = N30,696.70, Diagnostic = N56,400, Per-
sonnel = N53,340.40. Total Cost of Illness for one year for 37
patients = N1,360,369.80 (US $9,716.93). Total cost of treating
1000 patients = N1,360,369800.00 (US $9,716,930.00) aside
indirect cost among others per year. Average cost per patient =
N36,766.75 (US $262.62) (84.7% of N43,400.00 (US $310.0)
per capital income in Nigeria). Range; N2,618.44 (US $18.70)
and N268,572.81 (US $1918.38). N = Naira. CONCLUSION:
Spending an average of 84.7% of per capital income to treat an
illness annually is highly unfortunate as this further worsens the
quality of life of such patients. This call for good understanding
of the disease condition by the society to minimize the incidence
while ensuring compliance and also for improved policy by 
government.
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OBJECTIVES: The aim of this study was to collect cost data on
the complications associated with diabetes mellitus in Canada
and Australia for use in a published, validated computer simu-
lation model of the disease. METHODS: A search for costs data
was performed in PubMed to identify peer-reviewed cost data in
Canada and Australia published in the last ten years. Costs not
identiﬁed in the literature were gathered from published gov-
ernment reports (sources included reports from the Provincial
Ministry of Health in Ontario and Newfoundland). All costs
were inﬂated to 2004 values. Major complication costs are pre-
sented. RESULTS: The costs of diabetes complications are well
documented in Canada, but there is a paucity of published cost
data for Australia. No Australian cost data were identiﬁed, and
a specialist research program has been initiated to generate this
information. In Canada, the event costs for non-fatal myocardial
